1. Home
  2. ELBM vs VERU Comparison

ELBM vs VERU Comparison

Compare ELBM & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electra Battery Materials Corporation

ELBM

Electra Battery Materials Corporation

N/A

Current Price

$0.58

Market Cap

54.9M

Sector

Miscellaneous

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

N/A

Current Price

$2.59

Market Cap

48.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELBM
VERU
Founded
2011
1971
Country
Canada
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.9M
48.2M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
ELBM
VERU
Price
$0.58
$2.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$2.15
$22.50
AVG Volume (30 Days)
341.2K
271.2K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
$28.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$2.05
52 Week High
$8.70
$7.33

Technical Indicators

Market Signals
Indicator
ELBM
VERU
Relative Strength Index (RSI) 50.54 50.65
Support Level $0.56 $2.12
Resistance Level $0.60 $2.67
Average True Range (ATR) 0.04 0.14
MACD 0.00 0.04
Stochastic Oscillator 51.97 52.84

Price Performance

Historical Comparison
ELBM
VERU

About ELBM Electra Battery Materials Corporation

Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry. The Company's operating segments are Refinery, Exploration and Evaluation, Corporate and Other.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: